Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Werewolf Therapeutics Inc. Common Stock
HOWL | US
0.38
USD-0.01
-2.65%
HOWL | US
Loading StockChartView...
About Werewolf Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
08/06/2026
Close
0.38
Open
0.39
High
0.42
Low
0.37
Werewolf Therapeutics Inc. a biopharmaceutical company develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company through its proprietary PREDATOR platform designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124 a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330 a conditionally activated Interleukin-12 INDUKINE molecule which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898 a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712 an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics Inc. was incorporated in 2017 and is headquartered in Watertown Massachusetts.
View LessHOWL | US
Risk
83.2
Sharpe
-0.77
Luna's Score
33/100
Recommendation
Sell
Luna says (HOWL | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
82.9%1 month
83.2%3 months
100.1%6 months
104.3%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.86
Debt to equity
0.35
Debt to assets
0.24
Ent. to EBITDA
0.57
Ent. to rev.
0.67
PEG
-
Other Fundamentals
EBITDA
-56.51M
MarketCap
16.69M
MarketCap(USD)
16.69M
Div. yield
-
Op. margin
-1.66K
Erngs. growth
-
Rev. growth
-85.90
Ret. on equity
-48.27
Short ratio
7.94
Short perc.
4.06
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.13
Range1M
0.35
Range3M
0.77
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.17
Price X volume
264.90K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.57 | 0.53 | Par |
| Ent. to Revenue | 0.67 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.86 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 100.08 | 72.80 | Riskier |
| Debt to Equity | 0.35 | -1.23 | Expensive |
| Debt to Assets | 0.24 | 0.25 | Par |
| Market Cap | 16.69M | 3.66B | Emerging |
